At the crossroads of cutting-edge materials science and advanced biomedical engineering, Jack Maughan is building tools that could reshape how we treat and interact with the brain. A postdoctoral researcher with a background in nanoscience and tissue engineering, Jack is exploring how graphene-based microneedles can enable next-generation neural interfaces devices that could one day treat neurological disorders, restore movement, and even enhance human-machine communication.
PRESS RELEASE - Strong collaboration among clinical, academic and industrial partners brings Europe a step closer to cost-effective point-of-care diagnostics for Alzheimer’s Disease.
Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.
With a nearly €6 million budget, 2D-BioPAD will develop a diagnostic system for early Alzheimer's disease detection. This Horizon Europe Research and Innovation Action funded by the European Union, officially commenced on October 2023 and will last 48 months.
The new biosensor looks like a small box connected to a mobile phone. This device can immediately detect even very small antibiotic residues, namely ampicillin, in water or dairy products.
Sebastian Klenk, a PhD student at the Graphene Flagship Partner University of the Bundeswehr Munich (Germany) is investigating biosignal detection with 2D carbon electrodes.
Graphene Flagship-affiliated researcher Ester Vázquez Fernández-Pacheco has been awarded a prize by the government of Spanish region Castilla-La Mancha for Investigation and Innovation in Science.
